Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9638964rdf:typepubmed:Citationlld:pubmed
pubmed-article:9638964lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0151744lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0020443lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0003591lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0074554lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0082608lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0205081lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:9638964lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:9638964pubmed:issue1lld:pubmed
pubmed-article:9638964pubmed:dateCreated1998-9-9lld:pubmed
pubmed-article:9638964pubmed:abstractTextInhibitors of HMG-CoA reductase are widely used for the treatment of hypercholesterolaemia and have recently been shown in the Scandinavian Simvastatin Survival Study (4S), to reduce coronary mortality as well as total mortality in CH D patients. Although a couple of studies have already established the efficacy ratio between simvastatin and fluvastatin, one of the newest members of this class, we considered it to be important to verify the comparative efficacy in patients with coronary artery disease in the same type of patients that were included in 4S particularly since the previous studies include rather few patients with CHD, 17-28% only.lld:pubmed
pubmed-article:9638964pubmed:languageenglld:pubmed
pubmed-article:9638964pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:citationSubsetIMlld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9638964pubmed:statusMEDLINElld:pubmed
pubmed-article:9638964pubmed:issn0001-5385lld:pubmed
pubmed-article:9638964pubmed:authorpubmed-author:TikkanenM JMJlld:pubmed
pubmed-article:9638964pubmed:authorpubmed-author:SigurdssonGGlld:pubmed
pubmed-article:9638964pubmed:authorpubmed-author:MiettinenT...lld:pubmed
pubmed-article:9638964pubmed:authorpubmed-author:Haraldsdottir...lld:pubmed
pubmed-article:9638964pubmed:authorpubmed-author:MelbergT HTHlld:pubmed
pubmed-article:9638964pubmed:authorpubmed-author:KristiansonK...lld:pubmed
pubmed-article:9638964pubmed:issnTypePrintlld:pubmed
pubmed-article:9638964pubmed:volume53lld:pubmed
pubmed-article:9638964pubmed:ownerNLMlld:pubmed
pubmed-article:9638964pubmed:authorsCompleteYlld:pubmed
pubmed-article:9638964pubmed:pagination7-14lld:pubmed
pubmed-article:9638964pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:meshHeadingpubmed-meshheading:9638964-...lld:pubmed
pubmed-article:9638964pubmed:year1998lld:pubmed
pubmed-article:9638964pubmed:articleTitleSimvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.lld:pubmed
pubmed-article:9638964pubmed:affiliationSjúkrahús Reykjavíkur Fossvogi, Reykjavik, Iceland.lld:pubmed
pubmed-article:9638964pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9638964pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9638964pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9638964pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:9638964pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:9638964pubmed:publicationTypeMulticenter Studylld:pubmed